GEO series
In vivo BMAL1 occupancy mapping using MACS-Calling Cards reveals disease-associated retargeting in Cln3Δex7/8 astrocytes
GSE318942
Homo sapiens; Mus musculus
Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other
65 samples
2026/05/01
GPL34284GPL16417GPL34290
Summary
Astrocytes maintain neuronal homeostasis through cellular programs that are frequently disrupted early in neurodegenerative disease, many of which are regulated by the circadian clock. The core clock transcription factor BMAL1 is required for normal astrocyte function, yet whether its regulatory activity is altered during neurodegeneration remains unclear. Moreover, astrocyte circadian gene expression patterns are profoundly reprogrammed in disease, yet the underlying mechanisms remain unclear, primarily due to a lack of methods for identifying DNA binding sites of BMAL1 in specific cell types in the brain. Here, we have developed an in vivo strategy to record transcription factor genomic occupancy specifically in astrocytes (MACS-Calling Cards, MACS-CC), and used it to map BMAL1 binding. We applied this strategy to the Cln3Δex7/8 mouse model of CLN3 disease, a fatal neurodegenerative disorder, which exhibits early astrocyte dysfunction prior to widespread neuronal loss as well as circadian dysregulation. This allowed us to test how the progressive pathological cascade caused by CLN3 deficiency reprograms BMAL1 binding in astrocytes. BMAL1 binding was extensively redistributed, with comparable numbers of wild-type-specific and disease-specific sites. Wild-type-specific BMAL1 binding was enriched near genes involved in circadian regulation and astrocyte differentiation, whereas disease-specific sites lacked coherent functional enrichment. Consistent with these changes, RNA-seq of sorted astrocytes revealed reduced expression of mature astrocyte markers in Cln3Δex7/8 mice. To define the mechanisms underlying BMAL1 retargeting in Cln3Δex7/8 astrocytes, we tested whether changes in chromatin accessibility could explain disease-associated gains and losses of BMAL1 binding. Although chromatin accessibility was broadly remodeled, differential accessibility did not predict BMAL1 binding gains or losses. Instead, motif analyses supported a model in which loss of normal cooperative transcription factor partnerships contributes to BMAL1 retargeting. Together, these findings demonstrate that MACS-CC enables in vivo transcription factor occupancy mapping in astrocytes and reveals the mechanisms behind early rewiring of circadian regulatory programs within a model of progressive pathology leading to neurodegeneration. Our data also shed new light on astrocyte dysfunction in CLN3 disease.
Download
NCBI GEO page ↗
{# Names what the click gives you. "Open in finder" meant nothing to a
visitor who arrived from a search engine and has never seen the tool. #}
Find more
RNA-seq datasets →
Similar datasets
- GSE289626 RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity 28 samples
- GSE250345 Functional inhibition of core spliceosomal machinery activates intronic premature cleavage and polyadenylation of pre-mRNAs 92 samples
- GSE241338 Genome-wide interference of chromatin architecture and Mediator in transcriptional bursting and gene network regulation 250 samples
- GSE245734 HNF4G and FOXA1 are context-specific drivers of pancreatic cancer progression 225 samples
- GSE290623 Opposing functions of distinct regulatory T cell subsets in colorectal cancer 142 samples
- GSE266349 Remodeling of Il4-Il13-Il5 locus underlies selective gene expression 138 samples
- GSE296242 Sustained MYB activity drives emergent enhancer activation and precise enhancer-promoter interactions 81 samples
- GSE218717 EZH2 gain-of-function mutations distort H3K27me3 landscapes and transform transcriptional responses to PRC2 inhibition. 244 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.